CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

封锁癌症研究医学药理学化学内科学受体

作者

Ferdinandos Skoulidis,Haniel A. Araújo,Minh Truong,Yu Qian,Xin Sun,Ana Galan Cobo,John T. Le,Meagan Montesion,Rachael Palmer,Nadine S. Jahchan,Joseph Juan,Chengyin Min,Yi Yu,Xuewen Pan,Kathryn C. Arbour,Natalie I. Vokes,Stephanie Schmidt,David Molkentine,Dwight H. Owen,R. Memmott,Pradnya D. Patil,Melina E. Marmarelis,Mark M. Awad,Joseph C. Murray,Jessica A. Hellyer,Justin F. Gainor,Anastasios Dimou,Christine M. Bestvina,Catherine A. Shu,Jonathan W. Riess,Collin M. Blakely,Chad V. Pecot,Laura Mezquita,Fabrizio Tabbó,Matthias Scheffler,Subba R. Digumarthy,Meghan J. Mooradian,Adrian G. Sacher,Sally C.M. Lau,Andreas Saltos,Julia Rotow,R. Johnson,Corinne Liu,Tyler F. Stewart,Sarah B. Goldberg,Jonathan Killam,Zenta Walther,Kurt A. Schalper,Kurtis D. Davies,Mark G. Woodcock,Valsamo Anagnostou,Kristen A. Marrone,Patrick M. Forde,Biagio Ricciuti,Deepti Venkatraman,Eliezer M. Van Allen,Amy L. Cummings,Jonathan W. Goldman,Hiram Shaish,Melanie Wain Kier,Sharyn I. Katz,Charu C. Aggarwal,Ying Ni,Joseph T. Azok,Jeremy Segal,Lauren L. Ritterhouse,Joel W. Neal,Ludovic Lacroix,Yasir Y. Elamin,Marcelo V. Negrão,Xiuning Le,Vincent K. Lam,Whitney E. Lewis,Haley N. Kemp,Brett Carter,Jack A. Roth,Stephen G. Swisher,Richard Lee,Teng Zhou,Alissa Poteete,Yifan Kong,Tomohiro Takehara,Alvaro Guimaraes Paula,Edwin R. Parra,Carmen Behrens,Ignacio I. Wistuba,Jianjun Zhang,George R. Blumenschein,Carl M. Gay,Lauren A. Byers,Don L. Gibbons,Anne S. Tsao,J. Jack Lee,Trever G. Bivona,D. Ross Camidge,Jhannelle E Gray,Natasha Lieghl,Benjamin Levy,Julie R. Brahmer,Marina Chiara Garassino,David R. Gandara,Edward B. Garon,Naiyer A. Rizvi,Giorgio V. Scagliotti,Jürgen Wolf,David Planchard,Benjamin Besse,Roy S. Herbst,Heather A. Wakelee,Nathan A. Pennell,Alice T. Shaw,Pasi A. Jänne,David P. Carbone,Matthew D. Hellmann,Charles M. Rudin,Lee A. Albacker,Helen Mann,Zhu Zhou,Zhongwu Lai,Ross Stewart,Solange Peters,Melissa L. Johnson,Kwok‐Kin Wong,Alan Huang,Monte M. Winslow,Michael Rosen,Ian P. Winters,Vassiliki A. Papadimitrakopoulou,Tina Cascone,Philip J. Jewsbury,John V. Heymach

出处

期刊：Nature [Springer Nature]
日期：2024-10-09 卷期号：635 (8038): 462-471 被引量：2

链接

nih.govdoi.org

标识

DOI：10.1038/s41586-024-07943-7

摘要

For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of anti-tumour activity and immune-related toxicities, when compared with treatment with PD-(L)1 inhibitors alone. However, there are currently no validated biomarkers to identify which patients will benefit from dual ICB

求助该文献

最长约 10秒，即可获得该文献文件

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

今日热心研友